Recombinant Human UCHL1 Protein，His

UCHL1 (Ubiquitin C-terminal hydrolase L1) is a prominent member of the ubiquitin-proteasome system, a crucial pathway for protein degradation and regulation within cells. Its role in maintaining cellular homeostasis and protein quality control has gained considerable attention, particularly in the context of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, where altered ubiquitination processes are implicated. UCHL1 is believed to function as a deubiquitinating enzyme, removing ubiquitin molecules from proteins, thus preventing their degradation and influencing signaling pathways. Research has shown that mutations and aberrant expression of UCHL1 are associated with increased susceptibility to neurodegeneration, making it a potential biomarker and therapeutic target. Recombinant UCHL1 protein studies are essential for elucidating its structural and functional properties, and for understanding its role in disease mechanisms. By producing UCHL1 as a recombinant protein, researchers can investigate its enzymatic activity, binding interactions, and the effects of post-translational modifications. Such studies are pivotal in designing drugs that modulate UCHL1 activity, thereby offering prospective therapeutic avenues for neurodegenerative disorders. Furthermore, the exploration of UCHL1's interactions with other ubiquitin-regulating proteins may provide insights into the intricate network of the ubiquitin-proteasome system and its implications in disease.